These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 27761881)

  • 1. Clinical Effectiveness and Impact on Insulin Therapy Cost After Addition of Dapagliflozin to Patients with Uncontrolled Type 2 Diabetes.
    Sosale B; Sosale A; Bhattacharyya A
    Diabetes Ther; 2016 Dec; 7(4):765-776. PubMed ID: 27761881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse Changes in HbA1c, Body Weight and Insulin Use in People with Type 1 Diabetes Mellitus Following Dapagliflozin Discontinuation in the DEPICT Clinical Trial Programme.
    Gordon J; Danne T; Beresford-Hulme L; Bennet H; Tank A; Edmonds C; Thorén F; Scheerer MF; McEwan P
    Diabetes Ther; 2020 May; 11(5):1135-1146. PubMed ID: 32274678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States.
    Neslusan C; Teschemaker A; Willis M; Johansen P; Vo L
    Diabetes Ther; 2018 Apr; 9(2):565-581. PubMed ID: 29411292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan.
    Chen JF; Peng YS; Chen CS; Tseng CH; Chen PC; Lee TI; Lu YC; Yang YS; Lin CL; Hung YJ; Chen ST; Lu CH; Yang CY; Chen CC; Lee CC; Hsiao PJ; Jiang JY; Tu ST
    PeerJ; 2020; 8():e9998. PubMed ID: 33240585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Clinical Effectiveness and Tolerability of Hydroxychloroquine 400 Mg in Uncontrolled Type 2 Diabetes Subjects who are not Willing to Initiate Insulin Therapy (HYQ-Real-World Study).
    Gupta A
    Curr Diabetes Rev; 2019; 15(6):510-519. PubMed ID: 31713476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus in Saudi Arabia: A Post Authorization Safety Study.
    Alguwaihes AM
    Diabetes Ther; 2021 Jul; 12(7):1979-1992. PubMed ID: 34118010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK.
    Evans M; Achha S; Neslusan C
    Diabetes Ther; 2017 Oct; 8(5):1175-1185. PubMed ID: 28948541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea.
    Han E; Kim A; Lee SJ; Kim JY; Kim JH; Lee WJ; Lee BW
    Diabetes Ther; 2018 Aug; 9(4):1689-1701. PubMed ID: 29998370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents.
    Vivian EM
    Drugs Context; 2014; 3():212264. PubMed ID: 25598831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Dapagliflozin Therapy on Renal Protection and Kidney Morphology in Patients With Uncontrolled Type 2 Diabetes Mellitus.
    Sugiyama S; Jinnouchi H; Kurinami N; Hieshima K; Yoshida A; Jinnouchi K; Tanaka M; Nishimura H; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T
    J Clin Med Res; 2018 Jun; 10(6):466-477. PubMed ID: 29707088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Combined Tofogliflozin and Glargine, Tofogliflozin Added to Insulin, and Insulin Dose-Increase Therapy in Uncontrolled Type 2 Diabetes.
    Suzuki K; Mitsuma Y; Sato T; Anraku T; Hatta M
    J Clin Med Res; 2016 Nov; 8(11):805-814. PubMed ID: 27738482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Utility Analysis of Saxagliptin/Dapagliflozin Versus Gliclazide and Insulin Glargine: Economic Implications of the Outcomes of the CVD-Real Studies I and II.
    Torre E; Bruno GM; Di Matteo S; Martinotti C; Valentino MC; Bottaro LC; Colombo GL
    Health Serv Insights; 2020; 13():1178632920929982. PubMed ID: 32595277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycated Hemoglobin, Body Weight and Blood Pressure in Type 2 Diabetes Patients Initiating Dapagliflozin Treatment in Primary Care: A Retrospective Study.
    Wilding J; Bailey C; Rigney U; Blak B; Beekman W; Emmas C
    Diabetes Ther; 2016 Dec; 7(4):695-711. PubMed ID: 27585582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study.
    Ku EJ; Lee DH; Jeon HJ; Oh TK
    Diabetes Res Clin Pract; 2019 May; 151():65-73. PubMed ID: 30954510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study.
    Tobita H; Sato S; Miyake T; Ishihara S; Kinoshita Y
    Curr Ther Res Clin Exp; 2017; 87():13-19. PubMed ID: 28912902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus.
    Molugulu N; Yee LS; Ye YT; Khee TC; Nie LZ; Yee NJ; Yee TK; Liang TC; Kesharwani P
    Diabetes Res Clin Pract; 2017 Oct; 132():157-168. PubMed ID: 28797524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapagliflozin in patients with type 2 diabetes mellitus.
    Filippatos TD; Liberopoulos EN; Elisaf MS
    Ther Adv Endocrinol Metab; 2015 Feb; 6(1):29-41. PubMed ID: 25678954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapagliflozin improves cardiovascular risk factors in Emirati patients with T2DM.
    Nada AM; Younan MA
    Ther Adv Endocrinol Metab; 2021; 12():2042018821995364. PubMed ID: 33796252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Pragmatic Clinical Trial to Compare the Real-World Effectiveness of V-Go versus Standard Delivery of Insulin in Patients with Advanced Type 2 Diabetes.
    Cziraky MJ; Abbott S; Nguyen M; Larholt K; Apgar E; Wasser T; Strange P; Shi L; Harrison HC; Everitt B; Nowak L
    J Health Econ Outcomes Res; 2019; 6(2):70-83. PubMed ID: 32685581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations of Plasma Concentration Profiles of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-Transporter Type 2, with Its Effects in Japanese Patients with Type 2 Diabetes Mellitus.
    Hayakawa T; Kato KI; Kobuchi S; Kataoka K; Sakaeda T
    Pharmaceuticals (Basel); 2022 Feb; 15(2):. PubMed ID: 35215315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.